Manufacturer record
Wilcure Remedies Pvt Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
5 batches manufactured by Wilcure Remedies Pvt Ltd (Madhya Pradesh) were declared Not of Standard Quality between September 2022 and October 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
5 records linked to Wilcure Remedies Pvt Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Dicyclomine hydrochloride & Mefenamic Acid Tablets IP | WT-1025Mfg 2025-08 · Exp 2027-07 | The cited product is official in I.P which is not printed on the strips of above refered sample.Other | SDTL, PunjabState lab | Oct 2025 |
| Dicyclomine hydrochloride & Mefenamic Acid Tablets | WT-1026Mfg 2025-08 · Exp 2027-07 | The cited product is official in I.P which is not Printed on the strips of above refered sample.Other | SDTL, PunjabState lab | Oct 2025 |
| METRONIDAZOLE TABLETS IP 200 g | WT-341Mfg 2023-07 · Exp 2025-06 | DissolutionDissolution | CDTL HyderabadCDSCO lab | Nov 2023 |
| LEVOFLOXACIN TABLETS IP 500 mg | WT-460Mfg 2023-09 · Exp 2025-08 | DescriptionDescription | CDTL HyderabadCDSCO lab | Nov 2023 |
| Norfloxacin Tablets I.P. 400 mg | WT-215Mfg 2021-11 · Exp 2023-10 | Dissolution testDissolution | CDTL MumbaiCDSCO lab | Sep 2022 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.